How COVID Is Changing Clinical Trials

Amidst all the uncertainty about a COVID vaccine, at least this one thing is certain: it is changing how clinical trials are conducted.

Instead of taking years to move apotential vaccine from laboratory to trial, the US’s Operation Warp Speed has moved two of six prospective COVID vaccines into Phase 3 recruitment in under six months. Two more are expected to begin Phase 3 recruitment this month.

In the United Kingdom, a different type of clinical trial showed it is possible to enroll 12,000 patients, test several different existing treatment candidates and have the first significant results in fewer than 100 days.

Even given the substantial differences between the government-run health care system of the UK and the private, decentralized US system, there are lessons – “ideas,” Nicole Mather calls them in an article for the journal Nature – researchers here can apply to accelerate trials.

Describing how the UK’s RECOVERY trial went from concept to first, actionable results in such a short time, Mather identifies five differences with traditional trials:

  1. The trial protocol took only 20 pages to detail the design, and data and regulatory requirements. It was flexible enough to allow trial arms to be stopped or added.
  2. It got approvals in 9 days, versus the typical 30-60.
  3. Recruitment paperwork was simplified.
  4. Data collection and processing was accelerated through the UK’s DigiTrials hub, which provides centralized support for clinical trials.
  5. Results were quickly made public.

Though the RECOVERY program has its critics – objections center on releasing results without first being peer-reviewed and structural issues – Mather says it shows how a centralized health data system and a streamlined design and approval process can accelerate the timeline.

“We’ve gone so far towards managing risk that we’ve created layers of bureaucracy that absorb time and money, and, paradoxically, increase the risk that beneficial treatments are not tested,” she writes.

That view is echoed by Martin Landray, deputy chief investigator of RECOVERY, who said the way the National Institute for Health Research cut red tape was “fabulous.” “Many academic and commercial trials have accumulated so much extra baggage over the years, such as long case report forms and 10 page patient consent forms,” he said in an interview with The BMJ.

Digital entry for the RECOVERY trial made consent and subsequent data collection quick and simple, The BMJ article reports.

Leveraging data systems is an important lesson, says Mather, who is life-sciences lead at IBM Services in London, which was a partner in the DigiTrials project. Because of the UK’s National Health System, much information was already available for trial study patients, simplifying the participation process.

That would be a much greater challenge in the US because of its private medical system, although the strong push over the last decade to digitize medical records is making the portability of patient data easier.

The UK RECOVERY program has given momentum to accelerating clinical trial processes. To build on it, says Landray, “We now need to apply the lessons from this approach to other major health challenges such as heart disease, cancer, arthritis, and mental health.”

Photo by JC Gellidon on Unsplash

#WeAreGreenKey: Spotlight on Lucas Leitenberger
Architecture + Engineering

#WeAreGreenKey: Spotlight on Lucas Leitenberger

Biotech vs. Techbio: A Nexus of Biology and Tech
General Interest

Biotech vs. Techbio: A Nexus of Biology and Tech

Cancer Vaccines: A New Hope
General Interest

Cancer Vaccines: A New Hope

Navigating Quarterly Reviews with Confidence
General Interest

Navigating Quarterly Reviews with Confidence

#WeAreGreenKey: Spotlight on Meryl Schoen
General Interest Professional Support

#WeAreGreenKey: Spotlight on Meryl Schoen

Mastering Hiring Algorithms as a Candidate
General Interest

Mastering Hiring Algorithms as a Candidate

Tips for Creating Effective Corporate Videos for Social Media
General Interest

Tips for Creating Effective Corporate Videos for Social Media

The Power of Video on Corporate Social Media
General Interest

The Power of Video on Corporate Social Media

#WeAreGreenKey: Spotlight on Antonia Piazza
General Interest

#WeAreGreenKey: Spotlight on Antonia Piazza

Strategies for Equitable Employee Development
General Interest

Strategies for Equitable Employee Development

Anthropic Unveils Claude 3: Redefining AI Chatbots with Enhanced Capabilities
Information Technology

Anthropic Unveils Claude 3: Redefining AI Chatbots with Enhanced Capabilities

#WeAreGreenKey: Spotlight on Mike Bosco
Accounting + Finance General Interest

#WeAreGreenKey: Spotlight on Mike Bosco

Marketing Strategies: 2024 Trends and Strategies for Success
General Interest

Marketing Strategies: 2024 Trends and Strategies for Success

The Essence of Marketing Strategy: Driving Business Success (Part II)
General Interest

The Essence of Marketing Strategy: Driving Business Success (Part II)

The Essence of Marketing Strategy: Driving Business Success
General Interest

The Essence of Marketing Strategy: Driving Business Success

Mastering Task Prioritization for Stress Reduction
General Interest

Mastering Task Prioritization for Stress Reduction

Crafting the Future: Delving into AI as a College Major
General Interest Information Technology

Crafting the Future: Delving into AI as a College Major

Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team
General Interest Pharma

Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team

Leveraging LinkedIn Polls: A Strategic Tool for Business Insights
General Interest

Leveraging LinkedIn Polls: A Strategic Tool for Business Insights

#WeAreGreenKey: Spotlight on Kyle Gierke
General Interest Healthcare

#WeAreGreenKey: Spotlight on Kyle Gierke

Latest Blog Posts
View All Posts
#WeAreGreenKey: Spotlight on Lucas Leitenberger

#WeAreGreenKey: Spotlight on Lucas Leitenberger

Welcome back to #WeAreGreenKey, where we shine a spotlight on our powerhouse recruiting team.  We recently met up with Lucas...
Read More
Biotech vs. Techbio: A Nexus of Biology and Tech

Biotech vs. Techbio: A Nexus of Biology and Tech

In the dynamic world of scientific innovation, two terms have emerged as guiding lights: Biotech and Techbio. These terms encapsulate...
Read More
Cancer Vaccines: A New Hope

Cancer Vaccines: A New Hope

Cancer vaccines stand as a beacon of hope in the realm of cancer treatment, diverging from traditional vaccines designed to...
Read More